Price Disclosure Reductions for 2020 April Cycle
This summary only includes medicines taking a price disclosure reduction on 1 April 2020. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes below show percentage (%) price differences and ex-manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.
The Department is continuing to implement statutory pricing functions, including price disclosure reductions for the current and future cycles. Any queries or concerns should be sent to pricedisclosure@health.gov.au.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should note that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2020 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs in late January 2020.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2019 PBS approved ex-manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2019 will also take the reduction on 1 April 2020 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on 23 December 2019.
Indicative prices for 1 April 2020 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2020. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 April 2020 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2020.
It remains open for responsible persons to request a price increase. Further information about price increases can be found on the page Requesting a change to an existing price.
|
Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria) |
Legal Instrument MoA | Legal Instrument Form |
Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential April '20 PBS Price (AEMP) ($) per pharmaceutical item |
October '19 AEMP ($) |
Percentage difference between October '19 and April '20 PBS prices (AEMP) (%) per pharmaceutical item |
Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item No originator brand determined Does not meet 30 month clock |
Applicable Unadjusted Price Reduction 10% or 30% |
|---|---|---|---|---|---|---|---|---|---|
| abacavir with lamivudine | Oral | Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg | 290.55 | 14.29% | 249.03 | 290.55 | 14.29% | Does not meet 30 month clock | 10 |
| abacavir with lamivudine | Oral | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | 290.55 | 14.29% | 249.03 | 290.55 | 14.29% | Does not meet 30 month clock | 10 |
| acarbose | Oral | Tablet 100 mg | 25.69 | 14.50% | 21.96 | 25.69 | 14.52% | OWAPD | 10 |
| acarbose | Oral | Tablet 50 mg | 18.14 | 14.50% | 15.51 | 18.14 | 14.50% | OWAPD | 10 |
| aripiprazole | Oral | Tablet 10 mg | 74.47 | 13.33% | 64.54 | 74.47 | 13.33% | Does not meet 30 month clock | 10 |
| aripiprazole | Oral | Tablet 15 mg | 105.68 | 13.33% | 91.59 | 105.68 | 13.33% | Does not meet 30 month clock | 10 |
| aripiprazole | Oral | Tablet 20 mg | 128.64 | 13.33% | 111.49 | 128.64 | 13.33% | Does not meet 30 month clock | 10 |
| aripiprazole | Oral | Tablet 30 mg | 156.76 | 13.33% | 135.86 | 156.76 | 13.33% | Does not meet 30 month clock | 10 |
| atazanavir | Oral | Capsule 150 mg (as sulfate) | 334.67 | 10.23% | 300.43 | 334.67 | 10.23% | Does not meet 30 month clock | 10 |
| atazanavir | Oral | Capsule 200 mg (as sulfate) | 446.24 | 10.23% | 400.59 | 446.24 | 10.23% | Does not meet 30 month clock | 10 |
| atazanavir | Oral | Capsule 300 mg (as sulfate) | 334.67 | 10.23% | 300.43 | 334.67 | 10.23% | Does not meet 30 month clock | 10 |
| atomoxetine | Oral | Capsule 10 mg (as hydrochloride) | 41.65 | 13.17% | 36.16 | 41.65 | 13.18% | GWAPD | 10 |
| atomoxetine | Oral | Capsule 100 mg (as hydrochloride) | 54.14 | 13.17% | 47.01 | 54.14 | 13.17% | GWAPD | 10 |
| atomoxetine | Oral | Capsule 18 mg (as hydrochloride) | 41.65 | 13.17% | 36.16 | 41.65 | 13.18% | GWAPD | 10 |
| atomoxetine | Oral | Capsule 25 mg (as hydrochloride) | 41.65 | 13.17% | 36.16 | 41.65 | 13.18% | GWAPD | 10 |
| atomoxetine | Oral | Capsule 40 mg (as hydrochloride) | 41.65 | 13.17% | 36.16 | 41.65 | 13.18% | GWAPD | 10 |
| atomoxetine | Oral | Capsule 60 mg (as hydrochloride) | 41.65 | 13.17% | 36.16 | 41.65 | 13.18% | GWAPD | 10 |
| atomoxetine | Oral | Capsule 80 mg (as hydrochloride) | 54.14 | 13.17% | 47.01 | 54.14 | 13.17% | GWAPD | 10 |
| azacitidine | Injection | Powder for injection 100 mg | 217.64 | 16.60% | 181.51 | 217.64 | 16.60% | GWAPD | 10 |
| dexamethasone | Injection | Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | 5.69 | 38.39% | 3.51 | 5.69 | 38.31% | No originator brand determined | 30 |
| dexamethasone | Injection | Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL | 13.96 | 38.39% | 8.60 | 13.96 | 38.40% | No originator brand determined | 30 |
| entecavir | Oral | Tablet 0.5 mg (as monohydrate) | 168.85 | 28.19% | 121.25 | 144.49 | 16.08% | Does not meet 30 month clock | 10 |
| entecavir | Oral | Tablet 1 mg (as monohydrate) | 274.59 | 28.19% | 197.18 | 234.98 | 16.09% | Does not meet 30 month clock | 10 |
| eplerenone | Oral | Tablet 25 mg | 63.79 | 24.89% | 47.91 | 63.79 | 24.89% | GWAPD | 10 |
| eplerenone | Oral | Tablet 50 mg | 63.79 | 24.89% | 47.91 | 63.79 | 24.89% | GWAPD | 10 |
| ezetimibe | Oral | Tablet 10 mg | 29.44 | 40.34% | 17.56 | 20.86 | 15.82% | Does not meet 30 month clock | 10 |
| ganciclovir | Injection | Powder for I.V. infusion 500 mg (as sodium) | 200.67 | 21.08% | 158.37 | 200.67 | 21.08% | Does not meet 30 month clock | 10 |
| imatinib | Oral | Capsule 100 mg (as mesilate) | 851.25 | 51.11% | 416.18 | 666.44 | 37.55% | GWAPD | 10 |
| imatinib | Oral | Capsule 400 mg (as mesilate) | 1702.50 | 51.11% | 832.35 | 1332.89 | 37.55% | GWAPD | 10 |
| imatinib | Oral | Tablet 100 mg (as mesilate) | 851.25 | 51.11% | 416.18 | 666.44 | 37.55% | GWAPD | 10 |
| imatinib | Oral | Tablet 400 mg (as mesilate) | 1702.50 | 51.11% | 832.35 | 1332.89 | 37.55% | GWAPD | 10 |
| lincomycin | Injection | Injection 600 mg (as hydrochloride monohydrate) in 2 mL | 102.94 | 22.50% | 79.78 | 92.49 | 13.74% | Does not meet 30 month clock | 10 |
| moxonidine | Oral | Tablet 200 micrograms | 8.06 | 11.94% | 7.10 | 8.06 | 11.91% | Does not meet 30 month clock | 10 |
| moxonidine | Oral | Tablet 400 micrograms | 13.74 | 11.94% | 12.10 | 13.74 | 11.94% | Does not meet 30 month clock | 10 |
| naloxone | Injection | Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe | 34.36 | 19.17% | 27.77 | 34.36 | 19.18% | Does not meet 30 month clock | 10 |
| naloxone | Injection | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | 38.96 | 19.17% | 31.49 | 38.96 | 19.17% | Does not meet 30 month clock | 10 |
| olmesartan | Oral | Tablet containing olmesartan medoxomil 20 mg | 4.34 | 11.74% | 3.83 | 4.34 | 11.75% | Does not meet 30 month clock | 10 |
| olmesartan | Oral | Tablet containing olmesartan medoxomil 40 mg | 9.21 | 11.74% | 8.13 | 9.21 | 11.73% | Does not meet 30 month clock | 10 |
| rizatriptan | Oral | Tablet (orally disintegrating) 10 mg (as benzoate) | 4.57 | 10.44% | 4.09 | 4.57 | 10.50% | GWAPD | 10 |
| rizatriptan | Oral | Wafer 10 mg (as benzoate) | 4.57 | 10.44% | 4.09 | 4.57 | 10.50% | GWAPD | 10 |
| rosuvastatin | Oral | Tablet 20 mg (as calcium) | 7.31 | 30.04% | 5.11 | 7.31 | 30.10% | GWAPD | 30 |
| rosuvastatin | Oral | Tablet 40 mg (as calcium) | 10.43 | 30.04% | 7.30 | 10.43 | 30.01% | GWAPD | 30 |
| rosuvastatin | Oral | Tablet 5 mg (as calcium) | 3.50 | 30.04% | 2.45 | 3.50 | 30.00% | GWAPD | 30 |
| tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | 143.62 | 35.60% | 92.49 | 143.62 | 35.60% | Does not meet 30 month clock | 10 |
| tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | 143.62 | 35.60% | 92.49 | 143.62 | 35.60% | Does not meet 30 month clock | 10 |
| tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | 143.62 | 35.60% | 92.49 | 143.62 | 35.60% | Does not meet 30 month clock | 10 |
| tobramycin | Inhalation | Solution for inhalation 300 mg in 5 mL | 938.45 | 25.30% | 701.02 | 938.45 | 25.30% | GWAPD | 10 |
| valganciclovir | Oral | Tablet 450 mg (as hydrochloride) | 1040.88 | 31.45% | 713.52 | 902.27 | 20.92% | Does not meet 30 month clock | 10 |
| voriconazole | Oral | Tablet 200 mg | 957.50 | 24.10% | 726.74 | 957.50 | 24.10% | GWAPD | 10 |
| voriconazole | Oral | Tablet 50 mg | 239.38 | 24.10% | 181.69 | 239.38 | 24.10% | GWAPD | 10 |
| zoledronic acid | Injection | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | 173.89 | 32.14% | 118.00 | 132.37 | 10.86% | GWAPD | 10 |
| zoledronic acid | Injection | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL vial | 197.50 | 32.14% | 134.02 | 197.50 | 32.14% | GWAPD | 10 |
| zoledronic acid | Injection | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | 173.89 | 32.14% | 118.00 | 132.37 | 10.86% | GWAPD | 10 |
| zoledronic acid | Injection | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | 232.81 | 32.14% | 157.98 | 177.21 | 10.85% | GWAPD | 10 |
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2020 April cycle can be downloaded below.